PBI Signs Contract with UTEP for Cancer Treatment Methodology Protocol Shown to Greatly Increase Survival and Prevention of Breast Cancer Metastasis
Premier Biomedical Inc. (OTCQB:BIEI) signed a Patent License Agreement with the University of Texas El Paso (UTEP), covering the cancer treatment process called "CD152-LDMC" which the two entities have been developing in cooperation at the prestigious Border Biomedical Research Center, housed in UTEP's $45-million Bioscience Research Building.
View full press release